Cargando…
Do Physicians Have a Duty to Discuss Expanded Access to Investigational Drugs with their Patients? A Normative Analysis
Drawing on ethical and legal frameworks in the Netherlands, the United States and France, we examine whether physicians are expected to inform patients about potentially relevant opportunities for expanded access to investigational drugs. While we found no definitive legal obligation, we argue that...
Autores principales: | Vermeulen, Stefan F., Hordijk, Marjolijn, Visser, Ruben J., Bunnik, Eline M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209970/ https://www.ncbi.nlm.nih.gov/pubmed/37226748 http://dx.doi.org/10.1017/jme.2023.53 |
Ejemplares similares
-
Devil in the Details: Physician Duties and Expanded Access
por: Lynch, Holly Fernandez
Publicado: (2023) -
The ‘false hope’ argument in discussions on expanded access to investigational drugs: a critical assessment
por: Hordijk, Marjolijn, et al.
Publicado: (2022) -
Evaluation of vascular repair by tissue-engineered human acellular vessels or expanded polytetrafluoroethylene grafts in a porcine model of limb ischemia and reperfusion
por: Kirkton, Robert D., et al.
Publicado: (2023) -
The Role of Physicians in Expanded Access to Investigational Drugs: A Mixed-Methods Study of Physicians’ Views and Experiences in The Netherlands
por: Bunnik, Eline M., et al.
Publicado: (2021) -
HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand?
por: Whittle, Nigel, et al.
Publicado: (2014)